Alzheimer's disease: clinical trials and drug development

The Lancet Neurology

Volumn 9, Issue 7, 2010, Pages 702-716

  Mangialasche, Francesca ^a,b   Solomon, Alina ^a,c   Winblad, Bengt ^a   Mecocci, Patrizia ^b   Kivipelto, Miia ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; ACC 001; ACL 24; AF 267B; AL 108; AL 208; AMYLOID BETA PROTEIN; AN 1972; ANTIOXIDANT; AZD 103; BAPINEUZUMAB; BEGACESTAT; BETA SECRETASE INHIBITOR; BMS 708163; BRAIN DERIVED NEUROTROPHIC FACTOR; CAD 106; CEVIMELINE; CHF 5074; CHOLINERGIC RECEPTOR STIMULATING AGENT; CTS 21166; DONEPEZIL; E 2012; EHT 0202; ELND 005; EVP 6124; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GSK 933776; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISPRONICLINE; LADOSTIGIL; MABT 5102 A; MEMANTINE; MINOCYCLINE; MK 0752; N 031112; N 744; NICOTINIC AGENT; PF 04360365; PF 04447943; PF 3084014; PF 4494700; PHENSERINE; PIOGLITAZONE; PRX 03140; R 1450; RHODANINE; ROSIGLITAZONE; RS 0406; SEMAGACESTAT; SEN 1269; SP 233; TALSACLIDINE; TARENFLURBIL; UB 311; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 950; VALPROIC ACID;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG INDUSTRY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN TARGETING; REVIEW;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS;

EID: 77953518555     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70119-8     Document Type: Review

References (163)

1. Wimo A., Winblad B., and Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 6 (2010) 98-103
2. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 20 (2006) S12-S18
3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD005593.
4. Winblad B. Donepezil in severe Alzheimer's disease. J Alzheimers Dis Other Demen 24 (2009) 185-192
5. Wang B.S., Wang H., Wei Z.H., Song Y.Y., Zhang L., and Chen H.Z. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm 116 (2009) 457-465
6. Gao X., Zheng C.Y., Yang L., Tang X.C., and Zhang H.Y. Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. Free Radic Biol Med 46 (2009) 1454-1462
7. Wenk G.L., Parsons C.G., and Danysz W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17 (2006) 411-424
8. Pei J.J., Sjogren M., and Winblad B. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. Curr Opin Psychiatry 21 (2008) 555-561
9. Wu H.M., Tzeng N.S., Qian L., et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 34 (2009) 2344-2357
10. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
11. Mecocci P., Bladstrom A., and Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 24 (2009) 532-538
12. Winblad B., Jones R.W., Wirth Y., Stoffler A., and Mobius H.J. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24 (2007) 20-27
13. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
14. Atri A., Shaughnessy L.W., Locascio J.J., and Growdon J.H. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22 (2008) 209-221
15. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367 (2006) 1057-1065
16. Weinreb O., Mandel S., Bar-Am O., et al. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 6 (2009) 163-174
17. Bolognesi M.L., Cavalli A., and Melchiorre C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 6 (2009) 152-162
18. Rakover I., Arbel M., and Solomon B. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis 4 (2007) 392-402
19. Solomon B. A new target for Alzheimer's disease immunotherapy. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland. Neurobiol Aging 31 suppl 1 (2010) S29
20. Chang W.P., Downs D., Huang X.P., Da H., Fung K.M., and Tang J. Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. Faseb J 21 (2007) 3184-3196
21. Parkin E.T., Watt N.T., Hussain I., et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 104 (2007) 11062-11067
22. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., and Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457 (2009) 1128-1132
23. Lundkvist J., and Naslund J. Gamma-secretase: a complex target for Alzheimer's disease. Curr Opin Pharmacol 7 (2007) 112-118
24. Page R.M., Baumann K., Tomioka M., et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 283 (2008) 677-683
25. Kukar T.L., Ladd T.B., Bann M.A., et al. Substrate-targeting gamma-secretase modulators. Nature 453 (2008) 925-929
26. Madine J., Wang X., Brown D.R., and Middleton D.A. Evaluation of beta-alanine- and GABA-substituted peptides as inhibitors of disease-linked protein aggregation. Chembiochem 10 (2009) 1982-1987
27. Amijee H., and Scopes D.I. The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J Alzheimers Dis 17 (2009) 33-47
28. Lemere C.A., and Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat Rev Neurol 6 (2010) 108-119
29. Sanchez-Mejia R.O., Newman J.W., Toh S., et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11 (2008) 1311-1318
30. Roberson E.D., Scearce-Levie K., Palop J.J., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007) 750-754
31. Noble W., Garwood C., Stephenson J., Kinsey A.M., Hanger D.P., and Anderton B.H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. Faseb J 23 (2009) 739-750
32. Choi Y., Kim H.S., Shin K.Y., et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32 (2007) 2393-2404
33. Bulic B., Pickhardt M., Schmidt B., Mandelkow E.M., Waldmann H., and Mandelkow E. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 48 (2009) 1740-1752
34. Sigurdsson E.M. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15 (2008) 157-168
35. Zuccato C., and Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5 (2009) 311-322
36. Nagahara A.H., Merrill D.A., Coppola G., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15 (2009) 331-337
37. Karlén A., Karlsson T.E., Mattsson A., et al. Nogo receptor 1 regulates formation of lasting memories. PNAS 106 (2009) 20476-20481
38. Endo T., Tominaga T., and Olson L. Cortical changes following spinal cord injury with emphasis on the Nogo signaling system. Neuroscientist 15 (2009) 291-299
39. Park J.H., and Strittmatter S.M. Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer's transgenic mice. Curr Alzheimer Res 4 (2007) 568-570
40. Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4 (2008) 682-690
41. Klein J. Phenserine. Expert Opin Investig Drugs 16 (2007) 1087-1097
42. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease-the pivotal role of brain M1 receptors. Neurodegener Dis 5 (2008) 237-240
43. Hock C., Maddalena A., Raschig A., et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10 (2003) 1-6
44. Nitsch R.M., Deng M., Tennis M., Schoenfeld D., and Growdon J.H. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48 (2000) 913-918
45. Heinrich J.N., Butera J.A., Carrick T., et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 605 (2009) 53-56
46. Dunbar G.C., Inglis F., Kuchibhatla R., Sharma T., Tomlinson M., and Wamsley J. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 21 (2007) 171-178
47. Frolich L., Eckerwall G., Jonas N., and Sirocco-Investigators. A multicenter, double-blind, placebo-controlled phase IIB proof-of-concept dose-ranging study of AZD3480 and donepezil over 12 weeks in patients with mild to moderate Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P85
48. Baker J.D., Lenz R.A., Locke C., et al. ABT-089, a neuronal nicotinic receptor partial agonist, reverses scopolamine-induced cognitive deficits in healthy normal subjects. Alzheimers Dement 5 4 suppl 1 (2009) P325
49. Lenz R, Berry SM, Pritchett YL, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; Geneva, Switzerland; March 24-27, 2010. P100.
50. Hilt D., Gawryl M., Koenig G., and EVP-6124_StudyGroup. EVP-6124: safety, tolerability and cognitive effects of a novel A7 nicotinic receptor agonist in Alzheimer's disease patients on stable donepezil or rivastigmine therapy. International Conference on Alzheimer's Disease; Vienna, Austria (July 11-16, 2009). http://www.alzforum.org/drg/drc/detail.asp?id=127 (accessed Dec 15, 2009).
51. Cappai R., and Barnham K.J. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem Res 33 (2008) 526-532
52. Pimplikar S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 41 (2009) 1261-1268
53. Holmes C., Boche D., Wilkinson D., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
54. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110 (2009) 1129-1134
55. Landreth G., Jiang Q., Mandrekar S., and Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5 (2008) 481-489
56. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66 (2009) 300-305
57. Gold M., Alderton C., Zvartau-Hind M.E., et al. Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P86
58. Committee on Finance United States Senate. Staff report on GlaxoSmithKline and the diabetes drug Avandia. US Government Printing Office, Washington; January, 2010. 11th Congress, 2d session. Print 111-41. http://www.finance.senate.gov/library/prints/download/?id=6ebe979f-6376- 4d01-aa90-14483696fe54 (accessed March 15, 2010).
59. Tang J.J.N. Beta-secretase as target for amyloid-reduction therapy. Alzheimers Dement 5 4 suppl 1 (2009) P74
60. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother 9 (2009) 661-679
61. Henley D.B., May P.C., Dean R.A., and Siemers E.R. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 10 (2009) 1657-1664
62. Bateman R.J., Siemers E.R., Mawuenyega K.G., et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66 (2009) 48-54
63. Jacobsen S., Comery T., Kreft A., et al. GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P139
64. Imbimbo B.P. Alzheimer's disease: γ-secretase inhibitors. Drug Discov Today Ther Strateg 5 (2008) 169-175
65. Ereshefsky L., Jhee S.S., Yen M., and Moran S.V. The role of CSF dynabridging studies in developing new therapies for Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P414-P415
66. Wood K.M., Lanz T.A., Coffman K.J., et al. Efficacy of the novel γ-secretase inhibitor, PF-3084014, in reducing Aβ in brain, CSF, and plasma in guinea pigs and Tg2576 mice. Alzheimers Dement 4 (2008) T482
67. Soares H., Raha N., Sikpi M., et al. Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers. Alzheimers Dement 5 4 suppl 1 (2009) P252
68. Wang J., Ho L., and Passinetti G.M. The development of NIC5-15. A natural anti-diabetic agent, in the treatment of Alzheimer's disease. Alzheimers Dement 1 suppl 1 (2005) 62
69. Humanetics Pharmaceuticals. A disease modifying drug candidate for Alzheimer's disease. NIC5-15. http://www.humaneticscorp.com/ittrium/visit?path=A1xeb4x1y1xfcex1x65y1xf d4x1x65y1x126cx1x65 (accessed July 8, 2009).
70. Grossman H., Marzloff G., Luo X., LeRoith D., Sano M., and Pasinetti G. NIC5-15 as a treatment for Alzheimer's: safety, pharmacokinetics and clinical variables. Alzheimers Dement 5 4 suppl 1 (2009) P259
71. Green R.C., Schneider L.S., Amato D.A., et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302 (2009) 2557-2564
72. Imbimbo B.P. Why did tarenflurbil fail in Alzheimer's disease?. J Alzheimers Dis 17 (2009) 757-760
73. Imbimbo B.P., Hutter-Paier B., Villetti G., et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 156 (2009) 982-993
74. van Marum R.J. Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol 22 (2008) 265-274
75. Griffiths H.H., Morten I.J., and Hooper N.M. Emerging and potential therapies for Alzheimer's disease. Expert Opin Ther Targets 12 (2008) 693-704
76. Marcade M., Bourdin J., Loiseau N., et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 106 (2008) 392-404
77. Desire L., Marcade M., Peillon H., Drouin D., and Sol O. Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P255
78. Etcheberrigaray R., Tan M., Dewachter I., et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101 (2004) 11141-11146
79. Snow A.D., Cummings J., Lake T., et al. Exebryl-1: a novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P418
80. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8 (2007) 101-112
81. Shankar G.M., Li S., Mehta T.H., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14 (2008) 837-842
82. Aisen P.S., Saumier D., Briand R., et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67 (2006) 1757-1763
83. Aisen P, Gauthier S, Ferris S. et al. A phase III, placebo-controlled, double-blind, randomized trial of tramiprosate in the clinical management of patients with mild-to-moderate Alzheimer's disease (the Alphase study). 61st American Academy of Neurology annual meeting; Seattle, WA, USA; April 25-May 02, 2009. S32.003.
84. Alzheimer Research Forum, and McCaffrey P. Experts Slam Marketing of Tramiprosate (Alzhemed) as Nutraceutical (2008). http://www.alzforum.org/new/detail.asp?id=1937 (accessed Aug 4, 2009).
85. Adlard P.A., Cherny R.A., Finkelstein D.I., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59 (2008) 43-55
86. White A.R., Du T., Laughton K.M., et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281 (2006) 17670-17680
87. Lannfelt L., Blennow K., Zetterberg H., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7 (2008) 779-786
88. McLaurin J., Kierstead M.E., Brown M.E., et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12 (2006) 801-808
89. Garzone P., Koller M., Pastrak A., et al. Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men. Alzheimers Dement 5 4 suppl 1 (2009) P323
90. Elan. Elan and Transition Therapeutics announce modifications to ELND005 phase II clinical trials in Alzheimer's disease (2009). http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-pressroomartic le&ID=1365793&highlight (accessed Dec 15, 2009).
91. Mandel S.A., Amit T., Kalfon L., Reznichenko L., Weinreb O., and Youdim M.B. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis 15 (2008) 211-222
92. Gilman S., Koller M., Black R.S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
93. Winblad B., Minthon L., Floesser A., et al. Results of the first-in-man study with the active Aβ immunotherapy CAD106 in Alzheimer patients. Alzheimers Dement 5 4 suppl 1 (2009) P113
94. Muhs A., Hickman D.T., Pihlgren M., et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci USA 104 (2007) 9810-9815
95. Wang C.Y., Finstad C.L., Walfield A.M., et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine 25 (2007) 3041-3052
96. Schneeberger A., Mandler M., Otawa O., Zauner W., Mattner F., and Schmidt W. Development of affitope vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J Nutr Health Aging 13 (2009) 264-267
97. Wilcock D.M., and Colton C.A. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15 (2008) 555-569
98. Salloway S., Sperling R., Gilman S., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73 (2009) 2061-2070
99. Siemers E.R., Friedrich S., Dean R.A., et al. Safety, tolerability and biomarker effects of an ABeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Dement 4 4 suppl 2 (2008) T774
100. Bednar M., Zhao Q., Landen J.W., Billing C.B., Rohrbacher K., and Kupiec J.W. Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-modertae Alzheimer's disease: preliminary results. Alzheimers Dement 5 4 suppl 1 (2009) P157
101. Dodel R.C., Du Y., Depboylu C., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004) 1472-1474
102. Relkin N.R., Szabo P., Adamiak B., et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30 (2009) 1728-1736
103. Tsakanikas D., Shah K., Flores C., Assuras S., and Relkin N.R. Effects of uninterrupetd intravenous immunoglobulin treatment of Alzheimer's disease for nine months. Alzheimers Dement 4 4 suppl 2 (2008) T776
104. McElhaney J.E., and Effros R.B. Immunosenescence: what does it mean to health outcomes in older adults?. Curr Opin Immunol 21 (2009) 418-424
105. Fox N.C., Black R.S., Gilman S., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005) 1563-1572
106. Vellas B., Black R., Thal L.J., et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6 (2009) 144-151
107. Hashimoto M., Bogdanovic N., Volkmann I., Aoki M., Winblad B., and Tjernberg L.O. Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology. Acta Neuropathol 119 (2010) 543-554
108. Mudher A., and Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci 25 (2002) 22-26
109. Tariot P.N., and Aisen P.S. Can lithium or valproate untie tangles in Alzheimer's disease?. J Clin Psychiatry 70 (2009) 919-921
110. Tariot P., Aisen P., Cummings J., et al. The ADCS valproate neuroprotection trial: primary efficacy and safety results. Alzheimers Dement 5 4 suppl 1 (2009) P84-P85
111. Hampel H., Ewers M., Burger K., et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70 (2009) 922-931
112. Sereno L., Coma M., Rodriguez M., et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35 (2009) 359-367
113. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., and Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93 (1996) 11213-11218
114. Atamna H., Nguyen A., Schultz C., et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. Faseb J 22 (2008) 703-712
115. Deiana S., Harrington C.R., Wischik C.M., and Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology 202 (2009) 53-65
116. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nat Med 14 (2008) 894
117. Wischik C. Rember: issues in design of a phase 3 disease modifying clinical trial of tau aggregation inhibitor therapy in Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P74
118. Shiryaev N., Jouroukhin Y., Giladi E., et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34 (2009) 381-388
119. Gozes I., Divinski I., and Piltzer I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci 9 suppl 3 (2008) S3
120. Matsuoka Y., Gray A.J., Hirata-Fukae C., et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31 (2007) 165-170
121. Schmechel D.E., Gerard G., Vatakis N.G., et al. A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Alzheimers Dement 4 4 suppl 2 (2008) T483
122. Green K.N., Steffan J.S., Martinez-Coria H., et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 28 (2008) 11500-11510
123. Reddy P.H., and Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14 (2008) 45-53
124. Petersen C.H., Alikhani N., Behbahani H., et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 105 (2008) 13145-13150
125. Doody R.S., Gavrilova S.I., Sano M., et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372 (2008) 207-215
126. Medivation. Pfizer and Medivation announce results from two phase 3 studies in dimebon (latrepirdine*) Alzheimer's disease clinical development program (2010). http://investors.medivation.com/releasedetail.cfm?ReleaseID=448818 (accessed March 3, 2010).
127. Tariot P., Sabbagh M., Flitman S., Reyes P., Taber L., and Seely L. A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil. Alzheimers Dement 5 4 suppl 1 (2009) P251
128. Wu J., Li Q., and Bezprozvanny I. Evaluation of dimebon in cellular model of Huntington's disease. Mol Neurodegener 3 (2008) 15
129. Moreira P.I., Santos M.S., Moreno A., and Oliveira C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep 21 (2001) 789-800
130. Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., and Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993 (2003) 334-344
131. Zhang S, Hedskog L, Hansson-Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis (in press).
132. Cattaneo A., Capsoni S., and Paoletti F. Towards non invasive nerve growth factor therapies for Alzheimer's disease. J Alzheimers Dis 15 (2008) 255-283
133. Jonhagen M.E., Nordberg A., Amberla K., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9 (1998) 246-257
134. Olson L., Nordberg A., von Holst H., et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 4 (1992) 79-95
135. Tuszynski M.H., Thal L., Pay M., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11 (2005) 551-555
136. NsGene. Advanced encapsulated cell biodelivery product for Alzheimer's disease successfully implanted in six patients (2008). http://www.nsgene.dk/NsGene-5.aspx?M=News&PID=15&NewsID=40&P rinterfriendly=1 (accessed Aug 18, 2009).
137. Eriksdotter J.M., Linderoth B., Almqvist P., et al. Therapy of Alzheimer's disease with NGF. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland. Neurobiol Aging 31 suppl 1 (2010) S9
138. Yurko-Mauro K., McCarthy D., Bailey-Hall E., Nelson E.B., Blackwell A., and MIDAS-Investigators. Results of the MIDAS trial: effects of docosahexanoic acid on physiological and safety parameters in age-related cognitive decline. Alzheimers Dement 5 4 suppl 1 (2009) P84
139. Chiu C.C., Su K.P., Cheng T.C., et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 1538-1544
140. Quinn J.F., Raman R., Thomas R., et al. A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease. Alzheimers Dement 5 4 suppl 1 (2009) P84
141. Freund-Levi Y., Basun H., Cederholm T., et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23 (2008) 161-169
142. Freund-Levi Y., Eriksdotter-Jonhagen M., Cederholm T., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63 (2006) 1402-1408
143. Freund-Levi Y., Hjorth E., Lindberg C., et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dement Geriatr Cogn Disord 27 (2009) 481-490
144. Isaac M.G., Quinn R., and Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 3 (2008) CD002854.
145. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007) 842-857
146. Opii W.O., Joshi G., Head E., et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging 29 (2008) 51-70
147. Solomon A., and Kivipelto M. Cholesterol-modifying strategies for Alzheimer's disease. Expert Rev Neurother 9 (2009) 695-709
148. Feldman H.H., Doody R.S., Kivipelto M., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74 (2010) 956-964
149. Maher-Edwards G., Zvartau-Hind M., Hunter A.J., et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res (2009) 10.2174/1567210200438162050 published online Dec 31.
150. Alzheimer Research Forum. Drugs in clinical trials: PRX-03140 (2010). http://www.alzforum.org/dis/tre/drc/detail.asp?id=113 (accessed Jan 29, 2010).
151. Nicholas T., Evans R., Styren S., et al. PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: translation from non-clinical species to healthy human volunteers. Alzheimers Dement 5 4 suppl 1 (2009) P330
152. Bates K.A., Verdile G., Li Q.X., et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14 (2009) 469-486
153. Becker R.E., and Greig N.H. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res 5 (2008) 346-357
154. Schneider L.S., and Lahiri D.K. The perils of Alzheimer's drug development. Curr Alzheimer Res 6 (2009) 77-78
155. Schneider J.A., Arvanitakis Z., Leurgans S.E., and Bennett D.A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66 (2009) 200-208
156. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746
157. Schneider L.S., and Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 5 (2009) 388-397
158. Pilotto A., Franceschi M., D'Onofrio G., et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 73 (2009) 761-767
159. Lovestone S., Francis P., Kloszewska I., et al. AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 1180 (2009) 36-46
160. Becker R.E., and Greig N.H. Methodological error risks to neuropsychiatric clinical trials (2010). http://www.aristeatranslationalmedicine.com/Errors_and_Uncertainties.htm l (accessed April 15, 2010).
161. Querfurth H.W., and LaFerla F.M. Alzheimer's disease. N Engl J Med 362 (2010) 329-344
162. Lansbury Jr. P.T. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Nat Med 10 suppl (2004) S51-S57
163. Bolognesi M.L., Matera R., Minarini A., Rosini M., and Melchiorre C. Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol 13 (2009) 303-308